Proteome Sciences (AIM: PRM) Secures Over $1 Million Contract for Mass Spectrometry Services in Clinical Trial Analysis

2 min read | February 21, 2025 07:12 PM AEDT | By Team Kalkine Media

Google News:

Proteome Sciences (AIM: PRM) Secures Over $1 Million Contract for Mass Spectrometry Services in Clinical Trial Analysis — Image source: Shutterstock

Recent News

APA (ASX:APA), TCL (ASX:TCL): Why Infrastructure Dividend Stocks Conti...

BIS (ASX:BIS), MND (ASX:MND), RIC (ASX:RIC): Why Dividend Stocks Remai...

CAT (ASX:CAT), EIQ (ASX:EIQ), LIC (ASX:LIC): Why Insider Confidence Is...

BRN, XRO, EIQ: AI Stocks Face Real-World Adoption Test

Make Kalkine Media
My Trusted Source

Highlights:

Proteome Sciences secures contract worth over US$1m for clinical trial analysis.

Work will be performed under Good Clinical Laboratory Practice (GCLP) accreditation.

Significant portion of project expected to be completed by end of 2025.

Proteome Sciences (AIM:PRM) is pleased to announce that it has secured a contract with a US-based biopharmaceutical company for the provision of mass spectrometry services. The contract, valued at over US$1 million, will involve the analysis of samples for an ongoing clinical trial, leveraging Proteome Sciences' Good Clinical Laboratory Practice (GCLP) accreditation. The Company anticipates that a significant portion of the project will be completed within the current financial year and continue into 2026.

This latest contract win follows the announcement in April 2024 of the first contract with this customer. Richard Dennis, Chief Commercial Officer of Proteome Sciences, remarked on the growing demand for GCLP-compliant services from both US and European biopharmaceutical clients. He emphasized that this contract represents a targeted assay to monitor drug performance during a clinical trial, reinforcing the Company’s expanding footprint in the clinical trial services sector.

Proteome Sciences has built a strong reputation for its mass spectrometry services, particularly in the area of clinical trial sample analysis, where GCLP accreditation is crucial for compliance with regulatory standards. The contract with the US biopharmaceutical company is expected to generate further interest from similar organizations, positioning Proteome Sciences for continued growth in this specialized sector.

The Company anticipates additional contracts to follow in 2025, further establishing Proteome Sciences as a trusted partner in the biopharma industry for clinical trial sample analysis. This contract win marks another milestone in the Company’s strategy to expand its commercial offerings and strengthen its position in the global biopharmaceutical market.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.